Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03225963
Recruitment Status : Unknown
Verified July 2017 by Taichung Veterans General Hospital. Recruitment status was: Recruiting
Bevacizumab has become the standard of care of recurrent glioblastoma based on promising clinical trial results with with response rates up to 50% and progression-free survival up to 9 months. In our study, we set to find the serum angiogenesis biomarkers of bevacizumab response.
Condition or disease
Radiation: Chemoradiation with temozolomide
Pre-chemoradiation and post-chemoradiation peripheral blood will be obtained to see if there are some angiogenesis biomarker available for prediction of bevacizumab response later.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
20 Years to 85 Years (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Obtain peripheral blood pre-chemotherapy, mid-chemoradition and post-chemoraidtion
Age older than 20 year old.
Glioblastoma patients who will receive chemoradiation treatment.